Transpharmation has considerable understanding in preclinical cognition research gained through decades of experience running disease area portfolios for Alzheimer’s disease, Parkinson’s disease and Schizophrenia within GlaxoSmithKline. Importantly, our highly skilled technical staff appreciate the subtleties involved in evaluating rodent cognitive processes, ensuring all our assays are highly robust and reproducible.

In addition to our rodent-based cognitive assessments, Transpharmation offers specialized services utilizing an aged canine model to study naturally occurring cognitive decline, mirroring conditions like Canine Cognitive Dysfunction Syndrome. This model is invaluable for translational research, providing insights into age-related cognitive impairments and facilitating the development of therapeutic interventions. Our aged dog model has been instrumental in evaluating the efficacy of various compounds and dietary supplements aimed at mitigating cognitive deficits associated with aging.

We focus on delivering carefully selected cognition models which are disease-relevant thereby offering the option to evaluate NCEs against pharmacologically induced cognition impairments, (e.g scopolamine) or natural impairments, (age, test parametric manipulation) across multiple disease areas.

Examples of models we offer:

  • •
    Novel object recognition:
    1. temporal deficit
    2. pharmacological deficit, (scopolamine, sub-chronic PCP)
  • •
    Delayed-non-match to position
  • •
    Reversal learning
  • •
    Selective attention variable oddity task
  • •
    Motor reaching task
  • •
    Visual acuity contrast sensitivity task